HAVCR2 and COVID-19: Although there was no significant difference in frequency noted between progressive vs stable COVID-19 patients in our cohort, we demonstrated the enrichment of ISGs and a unique set of co-inhibitory receptors (LAG-3 and TIM-3, coded by HAVCR2) in progressive patients.